Pharma Exclusives Pressreleases
START and Advarra Unite to Deliver Unmatched Speed, Quality, and Predictability for Early-Phase Oncology Trials
Friday, July 25, 2025The START Center for Cancer Research START the leading global communitybased earlyphase oncology research network today announced a strategic partnership with Advarra the premier provider
Trixeo Aerosphere receives positive EU CHMP opinion as first inhaled medicine using next-generation propellant with near-zero Global Warming Potential
Friday, July 25, 2025AstraZenecas Trixeo Aerosphere budesonideglycopyrroniumformoterol fumarate or BGF already licensed for the treatment of chronic obstructive pulmonary disease COPD in adults has received a positive opinion
Coriolis Pharma Opens New Laboratory at Spark Life Science Campus in Morrisville, North Carolina
Wednesday, July 23, 2025Coriolis Pharma a globally operating Contract Research and Development Organization CRDO and a leader in formulation research and development for biopharmaceuticals today announced its intention to invest million
Lantern Pharma Reports Complete Response in Heavily Pre-Treated Lymphoma Patient with LP-284 in Phase 1 Clinical Trial
Wednesday, July 23, 2025Lantern Pharma Inc a clinicalstage oncology company leveraging its proprietary RADR artificial intelligence AI platform to systematically transform drug discovery paradigms today announces that a heavily pretreated patient with aggressive Grade nong...
Revolution Medicines Announces FDA Breakthrough Therapy Designation for Elironrasib
Wednesday, July 23, 2025Revolution Medicines Inca latestage clinical oncology company developing targeted therapies for patients with RASaddicted cancers today announced that the US Food and Drug Administration FDA has granted Breakthrough Therapy
AstraZeneca plans to invest $50 billion in America for medicines manufacturing and R&D
Tuesday, July 22, 2025AstraZeneca today announces billion of investment in the United States by building on Americas global leadership in medicines manufacturing and RD This investment is expected
Longeveron® Announces Licensing of New Cardiac Selective Induced Pluripotent Stem Cell Technology for Cardiovascular Disease
Tuesday, July 22, 2025Longeveron Inca clinical stage regenerative medicine biotechnology company developing cellular therapies for lifethreatening rare pediatric and chronic agingrelated conditions today announced that it has licensed an issued US patent
Biogen to Highlight Scientific Progress Across Alzheimer’s Disease at the Alzheimer’s Association International Conference 2025
Tuesday, July 22, 2025Biogen Inctoday announced upcoming scientific presentations at the Alzheimers Association International Conference AAIC taking place July in Toronto Canada Data on LEQEMBI lecanemab will include month results from the Clarity AD openlabel extension...
Tagrisso plus chemotherapy demonstrated statistically significant and clinically meaningful improvement in overall survival in EGFR-mutated advanced lung cancer
Monday, July 21, 2025Positive highlevel results from the final overall survival OS analysis of the FLAURA Phase III trial showed AstraZenecas Tagrisso osimertinib with the addition of pemetrexed and platinumbased chemotherapy demonstrated
Lexicon to Present Patient-reported Data on Diabetic Peripheral Neuropathic Pain (DPNP) at the 7th Annual Meeting of the American Society of Pain and Neuroscience (ASPN 2025)
Friday, July 18, 2025Lexicon Pharmaceuticals Inc today announced that data from a study of patients describing the impact of diabetic peripheral neuropathic pain DPNP despite treatment with standard of care will be presented
